Recently, the use of PARP1 inhibitors alone or in combination with other chemotherapeutic agents showed anti-tumor activity in rhabdomyosarcoma [32], malignant peripheral nerve sheath tumors [31] and Ewing sarcoma cells [24, 36, 37]. This evidence concerns the gene PARP1 and rhabdomyosarcoma.